SecBot SecBot
PRESS-RELEASE ·Filed May 6, 2026

PHG

Royal Philips
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The reiterated full-year outlook and 6% order intake growth suggest steady execution, but macro headwinds (tariffs, cost inflation) are pressuring margins. Monitor upcoming quarters for margin trajectory and any guidance revision given the uncertain tariff environment.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$27.23
T+0 close · May 6, 2026 · via day close
Latest settled
−3.67%
T+60 · $26.23
Vs SPY
−7.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $27.23entry
  2. T+1 · 6mo ago −4.00%α −3.69% · $26.14
  3. T+5 · 6mo ago −5.88%α −7.03% · $25.63
  4. T+20 · 6mo ago −4.55%α −7.72% · $25.99
  5. T+60 · 4mo ago −3.67%α −7.19% · $26.23

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Royal Philips reported Q1 2026 comparable sales growth of 4% to EUR 3.9 billion and adjusted EBITA margin expansion of 40 bps to 9.0%, with income from operations of EUR 241 million. The company reiterated its full-year 2026 outlook for 3%-4.5% comparable sales growth and 12.5%-13.0% adjusted EBITA margin. The EPS consensus of $0.19 per ADS is not directly comparable to the reported EUR-denominated per-share figures, so no EPS surprise is computed.

Key Financial Metrics

Revenue
$3.9B
est $3.9B · +0.5% · +4.0% YoY
Guidance
3%-4.5% comparable sales growth
maintained
Free Cash Flow
$28.0M

Key Facts

  • Q1 2026 comparable sales growth of 4% to EUR 3.9 billion
  • Adjusted EBITA margin expanded 40 bps to 9.0%
  • Comparable order intake grew 6%
  • Income from operations increased to EUR 241 million
  • Free cash flow of EUR 28 million
  • Full-year 2026 outlook reiterated: comparable sales growth 3%-4.5%, adjusted EBITA margin 12.5%-13.0%, free cash flow EUR 1.3-1.5 billion
  • EUR 126 million in productivity savings in the quarter
  • Share repurchase of up to 4 million shares (approx. EUR 91 million) for long-term incentive plans

Financial Impact

Q1 sales EUR 3.9B, income from operations EUR 241M, free cash flow EUR 28M; full-year outlook implies EUR 18.5-18.7B sales at midpoint

revenueoperating incomefree cash flowadjusted EBITA margin

Segment Breakdown

SegmentGrowth
Diagnosis & Treatment+2.0%
Connected Care+3.0%
Personal Health+9.0%

Risk Factors

  • Higher tariffs and cost inflation impacting margins, especially in Connected Care (margin down 60 bps)
  • Ongoing Philips Respironics-related proceedings and DOJ investigation excluded from outlook
  • Uncertain macro environment with potential IEEPA tariff refunds excluded from guidance

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3288473

US Market Status

Market Closed · Opens in 7h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026